董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen A. Sherwin | 男 | Director | 68 | 47.53万美元 | 未持股 | 2017-04-21 |
| George J. Morrow | 男 | Director | 65 | 46.72万美元 | 未持股 | 2017-04-21 |
| Stephen A. Sherwin | 男 | Director | 68 | 未披露 | 未持股 | 2017-04-21 |
| Corinne H. Nevinny | 女 | Director | 57 | 47.17万美元 | 未持股 | 2017-04-21 |
| Richard F. Pops | 男 | Director | 55 | 48.37万美元 | 未持股 | 2017-04-21 |
| Kevin C. Gorman | 男 | Chief Executive Officer and Director | 59 | 528.97万美元 | 未持股 | 2017-04-21 |
| Joseph A. Mollica | 男 | Director | 76 | 46.87万美元 | 未持股 | 2017-04-21 |
| Gary A. Lyons | 男 | Director | 66 | 45.70万美元 | 未持股 | 2017-04-21 |
| Alfred W. Sandrock, Jr. | 男 | Director | 59 | 47.07万美元 | 未持股 | 2017-04-21 |
| William H. Rastetter | 男 | Chairman of the Board | 69 | 56.88万美元 | 未持股 | 2017-04-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric Benevich | 男 | Chief Commercial Officer | 51 | 249.06万美元 | 未持股 | 2017-04-21 |
| David Alexandre C. Gros | 男 | President, Chief Operating Officer and Interim Chief Financial Officer | 44 | 未披露 | 未持股 | 2017-04-21 |
| Kyle Gano | 男 | Chief Business Development Officer | 44 | 未披露 | 未持股 | 2017-04-21 |
| Darin Lippoldt | 男 | Chief Legal Officer and Corporate Secretary | 51 | 未披露 | 未持股 | 2017-04-21 |
| Malcolm Lloyd Smith | 男 | Chief Regulatory Officer | 61 | 未披露 | 未持股 | 2017-04-21 |
| Kevin C. Gorman | 男 | Chief Executive Officer and Director | 59 | 528.97万美元 | 未持股 | 2017-04-21 |
| Christopher F. O'Brien | 男 | Chief Medical Officer | 60 | 354.06万美元 | 未持股 | 2017-04-21 |
| Haig P. Bozigian | 男 | Chief Development Officer | 59 | 271.69万美元 | 未持股 | 2017-04-21 |
| Dimitri E. Grigoriadis | 男 | Chief Research Officer | 59 | 332.59万美元 | 未持股 | 2017-04-21 |
董事简历
中英对照 | 中文 | 英文- Stephen A. Sherwin
-
Stephen A. Sherwin自2015年9月以来，Sherwin一直担任Neon Therapeutics, Inc.的董事会成员。Sherwin博士是旧金山加利福尼亚大学的临床医学教授，扎克伯格旧金山综合医院血液肿瘤科的一名志愿者主治医师。Sherwin博士目前也是Third Rock的风险合伙人，也是帕克癌症免疫治疗研究所科学指导委员会的成员。Sherwin博士曾于2001年担任Ceregene，Inc.的联合创始人和董事长，直到2013年被Sangamo Biosciences，Inc.收购。在此之前，Sherwin博士于1990年担任Cell Genesys，Inc.的董事长兼首席执行官，这是一家癌症免疫治疗公司，直到2009年与ANI Pharmaceuticals合并，公司前身为BioSante Pharmaceuticals，Inc.舍温博士还是安进公司于2006年收购的抗体公司Abgenix的联合创始人和董事长。舍温博士在过去五年中目前在Aduro Biotech，Inc.、Biogen，Inc.和Neurocrine Biosciences，Inc.的董事会任职，Sherwin博士还担任BiangnTe制药公司的董事，直到与阿尼制药公司合并，在2013个RigelP药学公司，VICA公司和VelaSTEM公司。Sherwin博士持有哈佛医学院的医学博士，以及生物学学士学位，来自耶鲁大学的优等生。于2025年08月26日获委任为信达生物制药独立非执行董事、战略委员会委员。
Stephen A. Sherwin,is a Clinical Professor of Medicine at UCSF (since 2010) and Volunteer Attending Physician at Zuckerberg San Francisco General Hospital. As an Advisory Partner at Third Rock Ventures (since 2016), he co-founded and chaired Ceregene (acquired by Sangamo, 2001–2013) and Abgenix (acquired by Amgen, 1996–2006), and was CEO of Cell Genesys (merged with BioSante, 1994–2009). He serves on the board of Neurocrine Biosciences (since 1999) and previously directed Epiphany Technology Acquisition Corp. (2022–2023), Bios Special Acquisition Corp. (2021–2023), and Aduro Biotech (2015–2020). He holds a BA in Biology from Yale and an MD from Harvard Medical School. - Stephen A. Sherwin自2015年9月以来，Sherwin一直担任Neon Therapeutics, Inc.的董事会成员。Sherwin博士是旧金山加利福尼亚大学的临床医学教授，扎克伯格旧金山综合医院血液肿瘤科的一名志愿者主治医师。Sherwin博士目前也是Third Rock的风险合伙人，也是帕克癌症免疫治疗研究所科学指导委员会的成员。Sherwin博士曾于2001年担任Ceregene，Inc.的联合创始人和董事长，直到2013年被Sangamo Biosciences，Inc.收购。在此之前，Sherwin博士于1990年担任Cell Genesys，Inc.的董事长兼首席执行官，这是一家癌症免疫治疗公司，直到2009年与ANI Pharmaceuticals合并，公司前身为BioSante Pharmaceuticals，Inc.舍温博士还是安进公司于2006年收购的抗体公司Abgenix的联合创始人和董事长。舍温博士在过去五年中目前在Aduro Biotech，Inc.、Biogen，Inc.和Neurocrine Biosciences，Inc.的董事会任职，Sherwin博士还担任BiangnTe制药公司的董事，直到与阿尼制药公司合并，在2013个RigelP药学公司，VICA公司和VelaSTEM公司。Sherwin博士持有哈佛医学院的医学博士，以及生物学学士学位，来自耶鲁大学的优等生。于2025年08月26日获委任为信达生物制药独立非执行董事、战略委员会委员。
- Stephen A. Sherwin,is a Clinical Professor of Medicine at UCSF (since 2010) and Volunteer Attending Physician at Zuckerberg San Francisco General Hospital. As an Advisory Partner at Third Rock Ventures (since 2016), he co-founded and chaired Ceregene (acquired by Sangamo, 2001–2013) and Abgenix (acquired by Amgen, 1996–2006), and was CEO of Cell Genesys (merged with BioSante, 1994–2009). He serves on the board of Neurocrine Biosciences (since 1999) and previously directed Epiphany Technology Acquisition Corp. (2022–2023), Bios Special Acquisition Corp. (2021–2023), and Aduro Biotech (2015–2020). He holds a BA in Biology from Yale and an MD from Harvard Medical School.
- George J. Morrow
-
George J. Morrow曾担任全球生物技术公司Amgen Inc.，2003-2011年；Global Commercial Operations执行副总裁和Worldwide Sales and Marketing执行副总裁（2001-2003年）。1992年至2001年，Morrow先生在GlaxoSmithKline Inc.及其子公司担任多个领导职务，包括Glaxo Wellcome Inc.总裁兼首席执行官。Morrow在杜克大学获得了工商管理硕士学位，在布林莫尔学院获得了生物化学硕士学位，在长岛大学南安普顿学院获得了化学学士学位。
George J. Morrow,served as the Executive Vice President of Global Commercial Operations at Amgen Inc., a leading biotechnology company, from 2003 to 2011. In this role, he was responsible for overseeing the company's global marketing strategies and operations, driving growth and expanding Amgen's reach in the biopharmaceutical market.Prior to his position in global commercial operations, George held the role of Executive Vice President of Worldwide Sales and Marketing at Amgen from 2001 to 2003, where he focused on enhancing the company's sales strategies and marketing initiatives.Before joining Amgen, George had a notable career at Glaxo Wellcome Inc. and GlaxoSmithKline Inc., where he held various positions, culminating in his role as President and Chief Executive Officer. His leadership at Glaxo Wellcome, a major biopharmaceutical company, helped to shape its market presence during a critical period of growth and innovation.George has also contributed to several boards, serving on the boards of Neurocrine Biosciences, Inc. since 2015, Vical, Inc. from 2012 to 2019, Otonomy, Inc. from 2015 to 2018, and Human Genome Sciences, Inc. He has also been involved with Glaxo Wellcome, Inc., Safeway, Inc., and National Commerce Bank.He holds a Bachelor of Science degree in Chemistry from Southampton College, Long Island University, a Master of Business Administration (MBA) from Duke University, and a Master of Science in Biochemistry from Bryn Mawr College. - George J. Morrow曾担任全球生物技术公司Amgen Inc.，2003-2011年；Global Commercial Operations执行副总裁和Worldwide Sales and Marketing执行副总裁（2001-2003年）。1992年至2001年，Morrow先生在GlaxoSmithKline Inc.及其子公司担任多个领导职务，包括Glaxo Wellcome Inc.总裁兼首席执行官。Morrow在杜克大学获得了工商管理硕士学位，在布林莫尔学院获得了生物化学硕士学位，在长岛大学南安普顿学院获得了化学学士学位。
- George J. Morrow,served as the Executive Vice President of Global Commercial Operations at Amgen Inc., a leading biotechnology company, from 2003 to 2011. In this role, he was responsible for overseeing the company's global marketing strategies and operations, driving growth and expanding Amgen's reach in the biopharmaceutical market.Prior to his position in global commercial operations, George held the role of Executive Vice President of Worldwide Sales and Marketing at Amgen from 2001 to 2003, where he focused on enhancing the company's sales strategies and marketing initiatives.Before joining Amgen, George had a notable career at Glaxo Wellcome Inc. and GlaxoSmithKline Inc., where he held various positions, culminating in his role as President and Chief Executive Officer. His leadership at Glaxo Wellcome, a major biopharmaceutical company, helped to shape its market presence during a critical period of growth and innovation.George has also contributed to several boards, serving on the boards of Neurocrine Biosciences, Inc. since 2015, Vical, Inc. from 2012 to 2019, Otonomy, Inc. from 2015 to 2018, and Human Genome Sciences, Inc. He has also been involved with Glaxo Wellcome, Inc., Safeway, Inc., and National Commerce Bank.He holds a Bachelor of Science degree in Chemistry from Southampton College, Long Island University, a Master of Business Administration (MBA) from Duke University, and a Master of Science in Biochemistry from Bryn Mawr College.
- Stephen A. Sherwin
-
Stephen A. Sherwin自1999年4月加入Biogen Idec Inc.董事会。Sherwin博士目前在生命科学行业做咨询工作，同时参与病人护理和内科肿瘤专业教学。他是旧金山加利福尼亚大学医学院主任医师，还是旧金山综合医院血液肿瘤科志愿主治医师。Sherwin博士目前加入了 Biogen Idec公司， Rigel制药公司， Verastem股份有限公司和Vical股份有限公司董事会，同时也是生物技术工业组织荣誉主席和董事会成员。从1990年开始直到CellGenesy在2009年与BioSante制药公司合并，Sherwin博士先前曾担任专注于癌症免疫疗法的CellGenesy公司的董事长兼首席执行官。Sherwin博士曾于2001年担任Ceregene，Inc.的联合创始人和董事长，直到2013年被Sangamo Biosciences，Inc.收购。同时他也是Abgenix公司的董事长和共同创始人之一，该公司后来于2006年被Amgen公司收购；也是专攻基因疗法的Ceregene公司的主席和共同创始人之一，该公司于2013年被Sangamo生物科学公司收购。1983年至1990年，Sherwin博士在Genentech的临床医学部担任不同职位，最近一个职位是副总裁。1983年之前，他任职于美国国家癌症研究所。Sherwin博士以最优成绩获耶鲁大学生物专业学士学位，哈佛医学院医学博士学位，同时在内科和内科肿瘤专业享有资格认证，耶鲁大学的优等生。
Stephen A. Sherwin currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin also currently serves as a venture partner with Third Rock Ventures, LLC. He previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo Biosciences, Inc. in 2013. He was also a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen Inc. in 2006. From 1990 to October 2009 he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company’s merger with BioSante Pharmaceuticals, Inc. now ANI Pharmaceuticals, Inc. in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. In addition, Dr. Sherwin previously served on the board of directors of the Biotechnology Industry Organization from 2001 to 2014 and as its chairman from 2009 to 2011. Dr. Sherwin currently serves as a director of Neurocrine Biosciences, Inc., a life sciences company. - Stephen A. Sherwin自1999年4月加入Biogen Idec Inc.董事会。Sherwin博士目前在生命科学行业做咨询工作，同时参与病人护理和内科肿瘤专业教学。他是旧金山加利福尼亚大学医学院主任医师，还是旧金山综合医院血液肿瘤科志愿主治医师。Sherwin博士目前加入了 Biogen Idec公司， Rigel制药公司， Verastem股份有限公司和Vical股份有限公司董事会，同时也是生物技术工业组织荣誉主席和董事会成员。从1990年开始直到CellGenesy在2009年与BioSante制药公司合并，Sherwin博士先前曾担任专注于癌症免疫疗法的CellGenesy公司的董事长兼首席执行官。Sherwin博士曾于2001年担任Ceregene，Inc.的联合创始人和董事长，直到2013年被Sangamo Biosciences，Inc.收购。同时他也是Abgenix公司的董事长和共同创始人之一，该公司后来于2006年被Amgen公司收购；也是专攻基因疗法的Ceregene公司的主席和共同创始人之一，该公司于2013年被Sangamo生物科学公司收购。1983年至1990年，Sherwin博士在Genentech的临床医学部担任不同职位，最近一个职位是副总裁。1983年之前，他任职于美国国家癌症研究所。Sherwin博士以最优成绩获耶鲁大学生物专业学士学位，哈佛医学院医学博士学位，同时在内科和内科肿瘤专业享有资格认证，耶鲁大学的优等生。
- Stephen A. Sherwin currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin also currently serves as a venture partner with Third Rock Ventures, LLC. He previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo Biosciences, Inc. in 2013. He was also a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen Inc. in 2006. From 1990 to October 2009 he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company’s merger with BioSante Pharmaceuticals, Inc. now ANI Pharmaceuticals, Inc. in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. In addition, Dr. Sherwin previously served on the board of directors of the Biotechnology Industry Organization from 2001 to 2014 and as its chairman from 2009 to 2011. Dr. Sherwin currently serves as a director of Neurocrine Biosciences, Inc., a life sciences company.
- Corinne H. Nevinny
-
Corinne H. Nevinny自2004年6月起担任董事会成员。Nevinny女士目前是私人风险投资公司LMNVC LLC的普通合伙人。2003年至2010年，Nevinny女士在Edwards Lifesciences, Inc.担任过多个职位，Edwards Lifesciences, Inc.是心脏瓣膜和血流动力学监测领域的全球领导者。她曾担任副总裁兼心脏外科系统和血管业务部门总经理，负责Edwards 的全球业务，并担任首席财务官和财务主管。在2003年加入Edwards之前，Nevinny女士是Tularik公司的副总裁兼首席财务官，Tularik致力于发现和开发基于基因调控的药物，并于2004年出售给Amgen, Inc.。在加入Tularik之前，她是投资银行Warburg Dillon Read LLC的医疗保健集团执行董事。Nevinny女士之前是Onyx Pharmaceuticals, Inc.的董事会成员，Onyx Pharmaceuticals, Inc.是一家专注于癌症治疗的生物制药公司，于2013年出售给安进，也是Avanir Pharmaceuticals, Inc.的董事会成员，后者是一家专注于中枢神经系统疾病的生物制药公司，于2015年被Otsuka Pharmaceutical收购。Nevinny在斯坦福大学获得工业工程学士学位，在哈佛商学院获得工商管理硕士学位。
Corinne H. Nevinny has served on the Board of Directors since June 2004. Ms. Nevinny is currently a General Partner of LMNVC LLC, a privately held venture firm. From 2003 to 2010 Ms. Nevinny held various positions at Edwards Lifesciences, Inc., the global leader in the science of heart valves and hemodynamic monitoring. She served as Corporate Vice President and the General Manager of the Cardiac Surgery Systems and Vascular business units, was responsible for Edwards' global operations and served as Chief Financial Officer and Treasurer. Before joining Edwards in 2003 Ms. Nevinny was Vice President, Chief Financial Officer of Tularik, Inc., a company involved in the discovery and development of drugs based on gene regulation, which was sold to Amgen, Inc. in 2004. Prior to joining Tularik, she was Executive Director-Health Care Group at Warburg Dillon Read LLC, an investment bank. Ms. Nevinny was previously on the Board of Directors of Onyx Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cancer that was sold to Amgen in 2013 and the Board of Directors of Avanir Pharmaceuticals, Inc., a biopharmaceutical company focused on central nervous system disorders that was acquired by Otsuka Pharmaceutical in 2015. Ms. Nevinny received her undergraduate degree in industrial engineering from Stanford University and her Master's degree in business administration from Harvard Business School. - Corinne H. Nevinny自2004年6月起担任董事会成员。Nevinny女士目前是私人风险投资公司LMNVC LLC的普通合伙人。2003年至2010年，Nevinny女士在Edwards Lifesciences, Inc.担任过多个职位，Edwards Lifesciences, Inc.是心脏瓣膜和血流动力学监测领域的全球领导者。她曾担任副总裁兼心脏外科系统和血管业务部门总经理，负责Edwards 的全球业务，并担任首席财务官和财务主管。在2003年加入Edwards之前，Nevinny女士是Tularik公司的副总裁兼首席财务官，Tularik致力于发现和开发基于基因调控的药物，并于2004年出售给Amgen, Inc.。在加入Tularik之前，她是投资银行Warburg Dillon Read LLC的医疗保健集团执行董事。Nevinny女士之前是Onyx Pharmaceuticals, Inc.的董事会成员，Onyx Pharmaceuticals, Inc.是一家专注于癌症治疗的生物制药公司，于2013年出售给安进，也是Avanir Pharmaceuticals, Inc.的董事会成员，后者是一家专注于中枢神经系统疾病的生物制药公司，于2015年被Otsuka Pharmaceutical收购。Nevinny在斯坦福大学获得工业工程学士学位，在哈佛商学院获得工商管理硕士学位。
- Corinne H. Nevinny has served on the Board of Directors since June 2004. Ms. Nevinny is currently a General Partner of LMNVC LLC, a privately held venture firm. From 2003 to 2010 Ms. Nevinny held various positions at Edwards Lifesciences, Inc., the global leader in the science of heart valves and hemodynamic monitoring. She served as Corporate Vice President and the General Manager of the Cardiac Surgery Systems and Vascular business units, was responsible for Edwards' global operations and served as Chief Financial Officer and Treasurer. Before joining Edwards in 2003 Ms. Nevinny was Vice President, Chief Financial Officer of Tularik, Inc., a company involved in the discovery and development of drugs based on gene regulation, which was sold to Amgen, Inc. in 2004. Prior to joining Tularik, she was Executive Director-Health Care Group at Warburg Dillon Read LLC, an investment bank. Ms. Nevinny was previously on the Board of Directors of Onyx Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cancer that was sold to Amgen in 2013 and the Board of Directors of Avanir Pharmaceuticals, Inc., a biopharmaceutical company focused on central nervous system disorders that was acquired by Otsuka Pharmaceutical in 2015. Ms. Nevinny received her undergraduate degree in industrial engineering from Stanford University and her Master's degree in business administration from Harvard Business School.
- Richard F. Pops
-
Richard F. Pops，1998年4月，他成为公司董事，目前是Alkermes, Inc.的主席和首席执行官。1991年2月，他加入Alkermes，担任首席执行官。在他的领导下，Alkermes已经从一个只有25名雇员的私人研究性公司成长为拥有1200多名员工的国际性的上市制药公司。Alkermes外，他目前还在专注于骨骼与新城代谢理疗的生物技术公司Acceleron Pharma, Inc.、专注于试验胚胎学的生物技术公司Epizyme Corporation以及Biotechnology Industry Organization和the Pharmaceutical Research and Manufacturers of America PhRMA担任董事。他在斯坦福大学（Stanford University）获得经济学学位。
Richard F. Pops,served as Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007 and as Chief Executive Officer and President from September 2009 to September 2011. Mr. Pops serves on the boards of directors of the Biotechnology Innovation Organization ("BIO") and the Pharmaceutical Research and Manufacturers of America ("PhRMA"). He previously served on the boards of directors of Acceleron Pharma, Inc., a publicly-traded biopharmaceutical company, from 2004 to December 2019, Epizyme, Inc., a publicly-traded biopharmaceutical company, from 2008 to October 2020, and the National Health Council, a nonprofit organization, from 2016 to December 2019. Mr. Pops also previously served on the advisory board of Polaris Venture Partners and as a member of the Harvard Medical School Board of Fellows through June 2012. - Richard F. Pops，1998年4月，他成为公司董事，目前是Alkermes, Inc.的主席和首席执行官。1991年2月，他加入Alkermes，担任首席执行官。在他的领导下，Alkermes已经从一个只有25名雇员的私人研究性公司成长为拥有1200多名员工的国际性的上市制药公司。Alkermes外，他目前还在专注于骨骼与新城代谢理疗的生物技术公司Acceleron Pharma, Inc.、专注于试验胚胎学的生物技术公司Epizyme Corporation以及Biotechnology Industry Organization和the Pharmaceutical Research and Manufacturers of America PhRMA担任董事。他在斯坦福大学（Stanford University）获得经济学学位。
- Richard F. Pops,served as Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007 and as Chief Executive Officer and President from September 2009 to September 2011. Mr. Pops serves on the boards of directors of the Biotechnology Innovation Organization ("BIO") and the Pharmaceutical Research and Manufacturers of America ("PhRMA"). He previously served on the boards of directors of Acceleron Pharma, Inc., a publicly-traded biopharmaceutical company, from 2004 to December 2019, Epizyme, Inc., a publicly-traded biopharmaceutical company, from 2008 to October 2020, and the National Health Council, a nonprofit organization, from 2016 to December 2019. Mr. Pops also previously served on the advisory board of Polaris Venture Partners and as a member of the Harvard Medical School Board of Fellows through June 2012.
- Kevin C. Gorman
-
Kevin C. Gorman，从1993年起，他就职于我公司。2006年前，他担任商业发展执行副总裁、首席商务官和高级副总裁；2006年9月起担任执行副总裁和首席运营官；2008年1月，被任命为总裁和首席执行官。从2008年1月起，他担任我公司董事。从1990至1993年，他是Avalon Medical Partners, L.P。的主席，负责我公司和其他几个生物技术公司如Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc.何ARIAD Pharmaceuticals, Inc.的早期创立。他在洛杉矶University of California获得免疫学博士学位和金融工商管理学硕士学位并在The Rockefeller University完成博士后培训。
Kevin C. Gorman, Ph.D. has been employed with the Company since 1993. He was appointed President and Chief Executive Officer in January 2008 after having served as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. He currently serves as Chief Executive Officer and has served on the Board of Directors since January 2008. From 1990 until 1993 Dr. Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of the Company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr. Gorman received his Ph.D. in immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University. - Kevin C. Gorman，从1993年起，他就职于我公司。2006年前，他担任商业发展执行副总裁、首席商务官和高级副总裁；2006年9月起担任执行副总裁和首席运营官；2008年1月，被任命为总裁和首席执行官。从2008年1月起，他担任我公司董事。从1990至1993年，他是Avalon Medical Partners, L.P。的主席，负责我公司和其他几个生物技术公司如Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc.何ARIAD Pharmaceuticals, Inc.的早期创立。他在洛杉矶University of California获得免疫学博士学位和金融工商管理学硕士学位并在The Rockefeller University完成博士后培训。
- Kevin C. Gorman, Ph.D. has been employed with the Company since 1993. He was appointed President and Chief Executive Officer in January 2008 after having served as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. He currently serves as Chief Executive Officer and has served on the Board of Directors since January 2008. From 1990 until 1993 Dr. Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of the Company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr. Gorman received his Ph.D. in immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.
- Joseph A. Mollica
-
Joseph A. Mollica从1997年起，他担任我公司董事并从1998至2011年担任董事会主席。从2004至2008年，他担任专注于药物开发与研发的生物制药公司Pharmacopeia Drug Discovery, Inc.的董事会主席；从1994年至2004年，担任Pharmacopeia Drug Discovery的前总公司Accelrys, Inc.的董事会主席、总裁和首席执行官；从1987年至1993年12月，担任DuPont Company医用品副总裁；从1991年至1993年，担任DuPont Merck Pharmaceutical Company的总裁和首席执行官。1966年至1986年，他就职于Ciba-Geigy Ltd.在多个职位工作过，责任日益增大，直到Ciba-Geigy的制药部高级副总裁。他目前是专注于肿瘤学的生物技术公司Celator Pharmaceuticals, Inc.的董事会主席并曾担任Cytogen Corporation, Redpoint Bio Corporation和Genencor International的董事。他在University of Rhode Island获得学士学位，在University of Wisconsin获得硕士学位和博士学位并在University of Rhode Island获得理学博士学位。
Joseph A. Mollica, Ph.D. has served on the Board of Directors since June 1997 and as Chairman of the Board from 1998 until 2011. From 2004 to 2008 Dr. Mollica served as the Chairman of the Board of Pharmacopeia Drug Discovery, Inc., a biopharmaceutical company focused on drug discovery and development. From 1994 to 2004 Dr. Mollica served as the Chairman of the Board of Directors, President and Chief Executive Officer of Accelrys, Inc., the former parent of Pharmacopeia Drug Discovery. From 1987 to December 1993 Dr. Mollica served as Vice President, Medical Products of DuPont Company and then as President and CEO of DuPont Merck Pharmaceutical Company from 1991 to 1993. At Ciba-Geigy Ltd., where he was employed from 1966 to 1986 he served in a variety of positions of increasing responsibility, rising to Senior Vice President of Ciba-Geigy’s Pharmaceutical Division. Dr. Mollica was previously a director of Cytogen Corporation, Celator Pharmaceuticals, Inc., Redpoint Bio Corporation and Genencor International. Over the past 20 years, Dr. Mollica has served on the boards of more than a dozen public, private and not-for-profit boards. He received his B.S. from the University of Rhode Island, his M.S. and Ph.D. from the University of Wisconsin and his Sc.D.h.c. from the University of Rhode Island. - Joseph A. Mollica从1997年起，他担任我公司董事并从1998至2011年担任董事会主席。从2004至2008年，他担任专注于药物开发与研发的生物制药公司Pharmacopeia Drug Discovery, Inc.的董事会主席；从1994年至2004年，担任Pharmacopeia Drug Discovery的前总公司Accelrys, Inc.的董事会主席、总裁和首席执行官；从1987年至1993年12月，担任DuPont Company医用品副总裁；从1991年至1993年，担任DuPont Merck Pharmaceutical Company的总裁和首席执行官。1966年至1986年，他就职于Ciba-Geigy Ltd.在多个职位工作过，责任日益增大，直到Ciba-Geigy的制药部高级副总裁。他目前是专注于肿瘤学的生物技术公司Celator Pharmaceuticals, Inc.的董事会主席并曾担任Cytogen Corporation, Redpoint Bio Corporation和Genencor International的董事。他在University of Rhode Island获得学士学位，在University of Wisconsin获得硕士学位和博士学位并在University of Rhode Island获得理学博士学位。
- Joseph A. Mollica, Ph.D. has served on the Board of Directors since June 1997 and as Chairman of the Board from 1998 until 2011. From 2004 to 2008 Dr. Mollica served as the Chairman of the Board of Pharmacopeia Drug Discovery, Inc., a biopharmaceutical company focused on drug discovery and development. From 1994 to 2004 Dr. Mollica served as the Chairman of the Board of Directors, President and Chief Executive Officer of Accelrys, Inc., the former parent of Pharmacopeia Drug Discovery. From 1987 to December 1993 Dr. Mollica served as Vice President, Medical Products of DuPont Company and then as President and CEO of DuPont Merck Pharmaceutical Company from 1991 to 1993. At Ciba-Geigy Ltd., where he was employed from 1966 to 1986 he served in a variety of positions of increasing responsibility, rising to Senior Vice President of Ciba-Geigy’s Pharmaceutical Division. Dr. Mollica was previously a director of Cytogen Corporation, Celator Pharmaceuticals, Inc., Redpoint Bio Corporation and Genencor International. Over the past 20 years, Dr. Mollica has served on the boards of more than a dozen public, private and not-for-profit boards. He received his B.S. from the University of Rhode Island, his M.S. and Ph.D. from the University of Wisconsin and his Sc.D.h.c. from the University of Rhode Island.
- Gary A. Lyons
-
Gary A. Lyons于2005年10月加入我们，担任董事。由于Lyons先生拥有丰富的谈判和开发合作关系的经验、专业的销售知识以及对候选药物市场进行的系列评估，所有这些对于我们获得业务成功都是至关重要的，董事会决议Lyons先生在某种程度上应该继续担任董事会成员。Lyons先生也是一家生物制药公司Neurocrine Biosciences, Inc.的董事会成员，1993年至2008年他曾是Neurocrine的首席执行官和董事会成员。Lyons先生也是两家生物制药公司Vical, Inc. 和 KaloBios Pharmaceuticals, Inc.以及一家生物技术公司Cytori Therapeutics, Inc.的董事会成员，2013年之前也曾是生物制药公司NeurogesX, Inc.的董事会主席。2008年7月起他担任生物制药公司PDL BioPharma, Inc.的董事会成员，后来Facet从PDL分离，2008年12月Lyons先生从PDL辞职并加入Facet Biotech Corporation的董事会，直到2010年4月Facet被Abbot Laboratories收购。2009年6月至2011年12月Lyons曾是生物制药公司Poniard Pharmaceuticals的董事会成员，1983年至1993年他在Genentech担任众多管理职务，包括业务开发副总裁和销售副总裁，同时也是Genentech执行委员会成员，他负责Genentech企业风险计划的国际许可、收购和合作，也负责两家子公司Genentech Canada, Inc. 和Genentech Limited Japan的运营。Lyons先生拥有University of New Hampshire 的海洋生物学学士学位以及Northwestern University的J.L. Kellogg Graduate School of Management的工商管理硕士学位。
Gary A. Lyons has served as the President and Chief Executive officer of GL Advisors, a biotechnology advisory firm, since 2015. Mr. Lyons served as a member of the board of directors of Vical Incorporated "Vical" from 1997 until the consummation of the merger with Private Brickell in August 2019. Previously, Mr. Lyons held various positions with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a biopharmaceutical company, for 16 years through January 2008 including President, Chief Executive Officer and member of the board of directors. From 1983 to 1993 Mr. Lyons held various executive positions at Genentech, Inc., a biotechnology company, including Vice President of Business Development, Vice President of Sales, and Director of Sales and Marketing. Mr. Lyons presently serves as a member of the board of directors of Neurocrine Biosciences, Inc. and Novus Therapeutics, Inc. (Nasdaq: NVUS) and is chairman of the board of directors of Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Retrophin, Inc. (Nasdaq: RTRX), all of which are publicly held biotechnology companies. In addition, Mr. Lyons served previously on the board of directors of PDL BioPharma, Inc., Facet Biotech Corporation, KaloBios Pharmaceuticals, Inc. and NeurogesX, Inc. Mr. Lyons holds a bachelor's degree in marine biology from the University of New Hampshire and an M.B.A. degree from Northwestern University, JL Kellogg Graduate School of Management. - Gary A. Lyons于2005年10月加入我们，担任董事。由于Lyons先生拥有丰富的谈判和开发合作关系的经验、专业的销售知识以及对候选药物市场进行的系列评估，所有这些对于我们获得业务成功都是至关重要的，董事会决议Lyons先生在某种程度上应该继续担任董事会成员。Lyons先生也是一家生物制药公司Neurocrine Biosciences, Inc.的董事会成员，1993年至2008年他曾是Neurocrine的首席执行官和董事会成员。Lyons先生也是两家生物制药公司Vical, Inc. 和 KaloBios Pharmaceuticals, Inc.以及一家生物技术公司Cytori Therapeutics, Inc.的董事会成员，2013年之前也曾是生物制药公司NeurogesX, Inc.的董事会主席。2008年7月起他担任生物制药公司PDL BioPharma, Inc.的董事会成员，后来Facet从PDL分离，2008年12月Lyons先生从PDL辞职并加入Facet Biotech Corporation的董事会，直到2010年4月Facet被Abbot Laboratories收购。2009年6月至2011年12月Lyons曾是生物制药公司Poniard Pharmaceuticals的董事会成员，1983年至1993年他在Genentech担任众多管理职务，包括业务开发副总裁和销售副总裁，同时也是Genentech执行委员会成员，他负责Genentech企业风险计划的国际许可、收购和合作，也负责两家子公司Genentech Canada, Inc. 和Genentech Limited Japan的运营。Lyons先生拥有University of New Hampshire 的海洋生物学学士学位以及Northwestern University的J.L. Kellogg Graduate School of Management的工商管理硕士学位。
- Gary A. Lyons has served as the President and Chief Executive officer of GL Advisors, a biotechnology advisory firm, since 2015. Mr. Lyons served as a member of the board of directors of Vical Incorporated "Vical" from 1997 until the consummation of the merger with Private Brickell in August 2019. Previously, Mr. Lyons held various positions with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a biopharmaceutical company, for 16 years through January 2008 including President, Chief Executive Officer and member of the board of directors. From 1983 to 1993 Mr. Lyons held various executive positions at Genentech, Inc., a biotechnology company, including Vice President of Business Development, Vice President of Sales, and Director of Sales and Marketing. Mr. Lyons presently serves as a member of the board of directors of Neurocrine Biosciences, Inc. and Novus Therapeutics, Inc. (Nasdaq: NVUS) and is chairman of the board of directors of Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Retrophin, Inc. (Nasdaq: RTRX), all of which are publicly held biotechnology companies. In addition, Mr. Lyons served previously on the board of directors of PDL BioPharma, Inc., Facet Biotech Corporation, KaloBios Pharmaceuticals, Inc. and NeurogesX, Inc. Mr. Lyons holds a bachelor's degree in marine biology from the University of New Hampshire and an M.B.A. degree from Northwestern University, JL Kellogg Graduate School of Management.
- Alfred W. Sandrock, Jr.
-
Alfred W. Sandrock, Jr.医学博士自2013年5月担任高级副总裁以及首席医疗官。从2012年2月到2013年4月， Sandrock博士担任高级副总裁以及首席医疗官。在此之前，自1998年加入公司后担任一些高级主管职务，包括开发科学部高级副总裁/神经学研发部高级副总裁以及神经临床开发部副总裁。Sandrock博士在斯坦福大学获得人类生物学学士学位，从哈佛大学医学院获得医学博士学位，从哈佛大学获得神经生物学博士。他在麻省综合医院完成了医药、神经学住院医师以及首席住院医师、神经肌肉疾病临床研究员以及临床神经生理肌电图学的实习。
Alfred W. Sandrock, Jr. has served as our Executive Vice President, Research and Development since September 2019. Prior to that, Dr. Sandrock served as our Chief Medical Officer from October 2017 to January 2020 as our Executive Vice President, Chief Medical Officer Neurology and Neurodegeneration from October 2015 to October 2017 as our Chief Medical Officer and Group Senior Vice President from April 2013 to October 2015 and as our Chief Medical Officer and Senior Vice President of Development Sciences from February 2012 to April 2013. Prior to that, Dr. Sandrock held several other senior executive positions since joining Biogen in 1998 including Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology. - Alfred W. Sandrock, Jr.医学博士自2013年5月担任高级副总裁以及首席医疗官。从2012年2月到2013年4月， Sandrock博士担任高级副总裁以及首席医疗官。在此之前，自1998年加入公司后担任一些高级主管职务，包括开发科学部高级副总裁/神经学研发部高级副总裁以及神经临床开发部副总裁。Sandrock博士在斯坦福大学获得人类生物学学士学位，从哈佛大学医学院获得医学博士学位，从哈佛大学获得神经生物学博士。他在麻省综合医院完成了医药、神经学住院医师以及首席住院医师、神经肌肉疾病临床研究员以及临床神经生理肌电图学的实习。
- Alfred W. Sandrock, Jr. has served as our Executive Vice President, Research and Development since September 2019. Prior to that, Dr. Sandrock served as our Chief Medical Officer from October 2017 to January 2020 as our Executive Vice President, Chief Medical Officer Neurology and Neurodegeneration from October 2015 to October 2017 as our Chief Medical Officer and Group Senior Vice President from April 2013 to October 2015 and as our Chief Medical Officer and Senior Vice President of Development Sciences from February 2012 to April 2013. Prior to that, Dr. Sandrock held several other senior executive positions since joining Biogen in 1998 including Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology.
- William H. Rastetter
-
William H. Rastetter， （哲学博士） ，2014年1月，担任公司董事。 他是一家名为 Receptos, Inc.的生物制药公司的共同创始人。2009年5月，他担任该公司的董事、董事会主席。2009年5月至2010年11月，他担任该公司的首席执行官。 2006年至2013年2月，他担任一家名为 Venrock Associates 的风险资本公司的合伙人。 2003年至2005年末，他是Biogen Idec公司的执行主席。Biogen Idec公司是由Biogen 公司和Idec Pharmaceuticals公司合并而成的。1986年，他加入Idec Pharmaceuticals公司，并担任主席、首席执行官。加入Idec之前， 他是 Genentech, Inc的企业风险投资主管、并在公司的科学部门任职。Rastetter博士现任 Illumina公司、 Neurocrine Biosciences公司和Fate Therapeutics 公司等生命科学上市公司的主席。他是Regulus Therapeutics公司的董事。这是一家生物制药上市公司。Rastetter博士在麻省理工大学和哈佛大学任教。他是斯隆管理学院的成员。他在麻省理工大学获得了化学学士，在哈佛大学获得了文学硕士和化学（哲学）博士。
William H. Rastetter has served on our Board of Directors since April 2013. From 2006 to February 2013 Dr. Rastetter served as a partner in the venture capital firm, Venrock. He served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003 and as Chairman from May 1996 to November 2003. Upon the merger of IDEC Pharmaceuticals and Biogen in November 2003 Dr. Rastetter served as Executive Chairman of Biogen Idec until the end of 2005. Dr. Rastetter served as chairman of the board of Illumina, Inc., a publicly held biotechnology company, from 2005 to January 2016 and served on its board of directors from 1998 to January 2016. He was a founder of Receptos, Inc. in 2009 and served as its chairman until the sale of the publicly held company to Celgene in 2015. Currently, he has served as the chairman of the board of directors of Fate Therapeutics, Inc., a publicly held biotechnology company, since November 2011; chairman of the board of directors of Neurocrine Biosciences, Inc., a publicly held biotechnology company, since May 2011 and on its board of directors since February 2010; on the board of directors of Grail, Inc., a privately-held company, since January 2016 and as its chairman from August 2017 to November 2018. Dr. Rastetter served on the board of directors of Cerulean Pharma Inc., a publicly held biotechnology company since January 2014 as its lead independent director from April 2014 to June 2016 and as its chairman from June 2016 until July 2017 when Cerulean and Daré Bioscience Inc. completed a reverse merger and he currently serves as chairman of the board of the surviving company, Daré Bioscience Inc., a publicly-traded company. In addition, he serves as an advisor to Illumina Ventures. He is the author of numerous scientific papers and patent applications in the fields of organic and bioorganic chemistry, protein and enzyme engineering, and biotechnology. Dr. Rastetter holds an S.B. in Chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in Chemistry from Harvard University. - William H. Rastetter， （哲学博士） ，2014年1月，担任公司董事。 他是一家名为 Receptos, Inc.的生物制药公司的共同创始人。2009年5月，他担任该公司的董事、董事会主席。2009年5月至2010年11月，他担任该公司的首席执行官。 2006年至2013年2月，他担任一家名为 Venrock Associates 的风险资本公司的合伙人。 2003年至2005年末，他是Biogen Idec公司的执行主席。Biogen Idec公司是由Biogen 公司和Idec Pharmaceuticals公司合并而成的。1986年，他加入Idec Pharmaceuticals公司，并担任主席、首席执行官。加入Idec之前， 他是 Genentech, Inc的企业风险投资主管、并在公司的科学部门任职。Rastetter博士现任 Illumina公司、 Neurocrine Biosciences公司和Fate Therapeutics 公司等生命科学上市公司的主席。他是Regulus Therapeutics公司的董事。这是一家生物制药上市公司。Rastetter博士在麻省理工大学和哈佛大学任教。他是斯隆管理学院的成员。他在麻省理工大学获得了化学学士，在哈佛大学获得了文学硕士和化学（哲学）博士。
- William H. Rastetter has served on our Board of Directors since April 2013. From 2006 to February 2013 Dr. Rastetter served as a partner in the venture capital firm, Venrock. He served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003 and as Chairman from May 1996 to November 2003. Upon the merger of IDEC Pharmaceuticals and Biogen in November 2003 Dr. Rastetter served as Executive Chairman of Biogen Idec until the end of 2005. Dr. Rastetter served as chairman of the board of Illumina, Inc., a publicly held biotechnology company, from 2005 to January 2016 and served on its board of directors from 1998 to January 2016. He was a founder of Receptos, Inc. in 2009 and served as its chairman until the sale of the publicly held company to Celgene in 2015. Currently, he has served as the chairman of the board of directors of Fate Therapeutics, Inc., a publicly held biotechnology company, since November 2011; chairman of the board of directors of Neurocrine Biosciences, Inc., a publicly held biotechnology company, since May 2011 and on its board of directors since February 2010; on the board of directors of Grail, Inc., a privately-held company, since January 2016 and as its chairman from August 2017 to November 2018. Dr. Rastetter served on the board of directors of Cerulean Pharma Inc., a publicly held biotechnology company since January 2014 as its lead independent director from April 2014 to June 2016 and as its chairman from June 2016 until July 2017 when Cerulean and Daré Bioscience Inc. completed a reverse merger and he currently serves as chairman of the board of the surviving company, Daré Bioscience Inc., a publicly-traded company. In addition, he serves as an advisor to Illumina Ventures. He is the author of numerous scientific papers and patent applications in the fields of organic and bioorganic chemistry, protein and enzyme engineering, and biotechnology. Dr. Rastetter holds an S.B. in Chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in Chemistry from Harvard University.
高管简历
中英对照 | 中文 | 英文- Eric Benevich
Eric Benevich于2015年5月被任命为首席商务官，负责Neurocrine产品投资组合的所有商业开发、市场营销和销售。Benevich之前从2005年到2015年在Avanir Pharmaceuticals任职，最近的职位是担任营销副总裁，负责NUEDEXTA以及CNS管道的商业化。Benevich有着20多年的制药行业经验，之前曾在Peninsula Pharmaceuticals, Amgen and AstraZeneca担任多个销售和营销职位，例如Enbrel，Epogen和Prilosec药物的销售。Benevich持有Washington State University国际商务文学学士学位。
Eric Benevich was appointed Chief Commercial Officer in May 2015 and is responsible for all aspects of commercial development, marketing and sales of the Neurocrine product portfolio. Previously, Mr. Benevich was at Avanir Pharmaceuticals, Inc., from 2005 to 2015 serving most recently as Vice President of Marketing where he was responsible for NUEDEXTA® and commercialization of their CNS pipeline. Mr. Benevich has over 20 years of experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at Peninsula Pharmaceuticals Inc., Amgen and AstraZeneca in the sales and marketing of drugs such as Enbrel®, Epogen® and Prilosec®. Mr. Benevich has a BBA in International Business from Washington State University.- Eric Benevich于2015年5月被任命为首席商务官，负责Neurocrine产品投资组合的所有商业开发、市场营销和销售。Benevich之前从2005年到2015年在Avanir Pharmaceuticals任职，最近的职位是担任营销副总裁，负责NUEDEXTA以及CNS管道的商业化。Benevich有着20多年的制药行业经验，之前曾在Peninsula Pharmaceuticals, Amgen and AstraZeneca担任多个销售和营销职位，例如Enbrel，Epogen和Prilosec药物的销售。Benevich持有Washington State University国际商务文学学士学位。
- Eric Benevich was appointed Chief Commercial Officer in May 2015 and is responsible for all aspects of commercial development, marketing and sales of the Neurocrine product portfolio. Previously, Mr. Benevich was at Avanir Pharmaceuticals, Inc., from 2005 to 2015 serving most recently as Vice President of Marketing where he was responsible for NUEDEXTA® and commercialization of their CNS pipeline. Mr. Benevich has over 20 years of experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at Peninsula Pharmaceuticals Inc., Amgen and AstraZeneca in the sales and marketing of drugs such as Enbrel®, Epogen® and Prilosec®. Mr. Benevich has a BBA in International Business from Washington State University.
- David Alexandre C. Gros
David AlexandreC.Gros，医学博士于2017年1月成为总裁兼首席运营官。在加入Neurocrine之前，他是高级副总裁，首席商务官和首席财务官，也是AlnylamPharmaceuticals，Inc.管理委员会的成员在2015年6月加入Alnylam之前，Gros博士曾于2011年9月至2015年6月担任赛诺菲（Sanofi SA）的执行Vice President兼首席战略官。任职Sanofi公司之前，他曾担任Centerview Partners公司（从2009年到2011年7月）、Merrill Lynch公司（从2006年到2009年）的负责生物技术和制药的投资银行职务，以及McKinsey&Company的管理咨询职务（此前）。Gros博士拥有约翰霍普金斯大学医学院的M.D.，哈佛商学院的M.B.A.和达特茅斯学院的B.A.。
David Alexandre C. Gros,has been a member of Eledon Pharmaceuticals, Inc. Board and the Company's Chief Executive Officer since September 2020. Dr. Gros served as an advisor to Eledon since May 2020. He joined Eledon from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where from May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a French manufacturer of pasta products. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.- David AlexandreC.Gros，医学博士于2017年1月成为总裁兼首席运营官。在加入Neurocrine之前，他是高级副总裁，首席商务官和首席财务官，也是AlnylamPharmaceuticals，Inc.管理委员会的成员在2015年6月加入Alnylam之前，Gros博士曾于2011年9月至2015年6月担任赛诺菲（Sanofi SA）的执行Vice President兼首席战略官。任职Sanofi公司之前，他曾担任Centerview Partners公司（从2009年到2011年7月）、Merrill Lynch公司（从2006年到2009年）的负责生物技术和制药的投资银行职务，以及McKinsey&Company的管理咨询职务（此前）。Gros博士拥有约翰霍普金斯大学医学院的M.D.，哈佛商学院的M.B.A.和达特茅斯学院的B.A.。
- David Alexandre C. Gros,has been a member of Eledon Pharmaceuticals, Inc. Board and the Company's Chief Executive Officer since September 2020. Dr. Gros served as an advisor to Eledon since May 2020. He joined Eledon from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where from May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a French manufacturer of pasta products. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.
- Kyle Gano
Kyle Gano博士于2011年被任命为首席业务发展官，负责所有业务和企业发展活动，包括管理与艾伯维公司、三菱田边制药公司和住友大日本制药公司正在进行的合作。Gano从2001年到2011年在Neurocrine担任多个职位，负责从营销分析到业务开发。Gano博士在俄勒冈大学（University of Oregon）获得化学学士学位，在华盛顿大学（University of Washington）获得生物化学学士学位，在洛杉矶加利福尼亚大学（University of California）获得有机化学博士学位和金融学工商管理硕士学位。
Kyle Gano, Ph.D. was appointed Chief Business Development Officer in 2011 and is responsible for all business and corporate development activities, including the management of ongoing collaborations with AbbVie, Mitsubishi Tanabe Pharma and Sumitomo Dainippon Pharma. From 2001 to 2011 Dr. Gano held several positions of increasing responsibility at Neurocrine spanning marketing analytics to business development. Dr. Gano received his B.S. in Chemistry from the University of Oregon, B.S. in Biochemistry from the University of Washington, and his Ph.D. in Organic Chemistry and M.B.A in Finance from the University of California, Los Angeles.- Kyle Gano博士于2011年被任命为首席业务发展官，负责所有业务和企业发展活动，包括管理与艾伯维公司、三菱田边制药公司和住友大日本制药公司正在进行的合作。Gano从2001年到2011年在Neurocrine担任多个职位，负责从营销分析到业务开发。Gano博士在俄勒冈大学（University of Oregon）获得化学学士学位，在华盛顿大学（University of Washington）获得生物化学学士学位，在洛杉矶加利福尼亚大学（University of California）获得有机化学博士学位和金融学工商管理硕士学位。
- Kyle Gano, Ph.D. was appointed Chief Business Development Officer in 2011 and is responsible for all business and corporate development activities, including the management of ongoing collaborations with AbbVie, Mitsubishi Tanabe Pharma and Sumitomo Dainippon Pharma. From 2001 to 2011 Dr. Gano held several positions of increasing responsibility at Neurocrine spanning marketing analytics to business development. Dr. Gano received his B.S. in Chemistry from the University of Oregon, B.S. in Biochemistry from the University of Washington, and his Ph.D. in Organic Chemistry and M.B.A in Finance from the University of California, Los Angeles.
- Darin Lippoldt
Darin Lippoldt于2014年10月被任命为首席法务官兼公司秘书，负责所有公司法律事务。在加入Neurocrine之前，Lippoldt先生曾担任他于2010年加入的Volcano Corporation公司的执行Vice President、总法律顾问和首席合规官。在加入Volcano之前，Lippoldt先生自2003年起担任AmylinPharmaceuticals，Inc.的助理总法律顾问。他此前曾在Fulbright&Jaworski LLP和Matthews and Branscomb，P.C.的律师事务所实践公司法和证券法。Lippoldt先生在圣玛丽大学（St.Mary’；s University）获得金融学学士学位、国际关系硕士学位和法学博士学位。
Darin Lippoldt was appointed Chief Legal Officer and Corporate Secretary in October 2014 and is responsible for all corporate legal matters. Prior to joining Neurocrine, Mr. Lippoldt served as Executive Vice President, General Counsel, and Chief Compliance Officer of Volcano Corporation, a company he joined in 2010. Prior to Volcano, Mr. Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law firms of Fulbright & Jaworski LLP and Matthews and Branscomb, P.C. Mr. Lippoldt received a B.B.A. in Finance, an M.A. in International Relations and a J.D. from St. Mary’s University.- Darin Lippoldt于2014年10月被任命为首席法务官兼公司秘书，负责所有公司法律事务。在加入Neurocrine之前，Lippoldt先生曾担任他于2010年加入的Volcano Corporation公司的执行Vice President、总法律顾问和首席合规官。在加入Volcano之前，Lippoldt先生自2003年起担任AmylinPharmaceuticals，Inc.的助理总法律顾问。他此前曾在Fulbright&Jaworski LLP和Matthews and Branscomb，P.C.的律师事务所实践公司法和证券法。Lippoldt先生在圣玛丽大学（St.Mary’；s University）获得金融学学士学位、国际关系硕士学位和法学博士学位。
- Darin Lippoldt was appointed Chief Legal Officer and Corporate Secretary in October 2014 and is responsible for all corporate legal matters. Prior to joining Neurocrine, Mr. Lippoldt served as Executive Vice President, General Counsel, and Chief Compliance Officer of Volcano Corporation, a company he joined in 2010. Prior to Volcano, Mr. Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law firms of Fulbright & Jaworski LLP and Matthews and Branscomb, P.C. Mr. Lippoldt received a B.B.A. in Finance, an M.A. in International Relations and a J.D. from St. Mary’s University.
- Malcolm Lloyd Smith
Malcolm Lloyd Smith，2012年8月起，担任本公司的监管事务、质量与临床高级副总裁；此前，自2008年8月起，担任监管事务与质量保证高级副总裁。2003年9月至2008年8月，他是Elan Pharmaceuticals, Inc. 的副总裁、全球监管事务总监；2002年3月至2003年8月，在英国担任其国际监管事务副总裁。此前，他在DuPont Pharma Ltd担任过愈益重要的多个职务，包括：全球监管事务副总裁，2001-2002；欧洲监管事务副总裁，1999-2001；欧洲监管事务高级总监，1994-1999；该公司在2001年被Bristol-Myers Squibb Company收购。1991-1994，他在特拉华州Wilmington的DuPont Merck Pharmaceutical Company担任国际监管事务总监；1984-1991，在瑞士的DuPont de Nemours International, S.A.担任监管事务与质量保证经理。他在University of Leeds担任药理学士学位，在Hatfield Polytechnic获得药理生物化学硕士学位。
Malcolm Lloyd Smith was appointed Chief Regulatory Officer in September 2014 and is responsible for regulatory affairs and quality assurance. Prior to joining Neurocrine, Mr. Lloyd-Smith served at Cadence Pharmaceuticals, Inc. as Senior Vice President, Regulatory Affairs, Quality and Clinical from August 2012 to September 2014 and previously as Senior Vice President, Regulatory Affairs and Quality Assurance from August 2008. Mr. Lloyd-Smith served as Vice President and Head of Global Regulatory Affairs for Elan Pharmaceuticals, Inc. from September 2003 to August 2008 after having served in the United Kingdom as its Vice President, International Regulatory Affairs from March 2002 to August 2003. Previously, Mr. Lloyd-Smith served in various positions of increasing responsibility with DuPont Pharmaceuticals in Germany, Switzerland, USA and UK. Mr. Lloyd-Smith holds a B.Sc. in Pharmacology from the University of Leeds and a M.Sc. in Pharmacological Biochemistry from Hatfield Polytechnic.- Malcolm Lloyd Smith，2012年8月起，担任本公司的监管事务、质量与临床高级副总裁；此前，自2008年8月起，担任监管事务与质量保证高级副总裁。2003年9月至2008年8月，他是Elan Pharmaceuticals, Inc. 的副总裁、全球监管事务总监；2002年3月至2003年8月，在英国担任其国际监管事务副总裁。此前，他在DuPont Pharma Ltd担任过愈益重要的多个职务，包括：全球监管事务副总裁，2001-2002；欧洲监管事务副总裁，1999-2001；欧洲监管事务高级总监，1994-1999；该公司在2001年被Bristol-Myers Squibb Company收购。1991-1994，他在特拉华州Wilmington的DuPont Merck Pharmaceutical Company担任国际监管事务总监；1984-1991，在瑞士的DuPont de Nemours International, S.A.担任监管事务与质量保证经理。他在University of Leeds担任药理学士学位，在Hatfield Polytechnic获得药理生物化学硕士学位。
- Malcolm Lloyd Smith was appointed Chief Regulatory Officer in September 2014 and is responsible for regulatory affairs and quality assurance. Prior to joining Neurocrine, Mr. Lloyd-Smith served at Cadence Pharmaceuticals, Inc. as Senior Vice President, Regulatory Affairs, Quality and Clinical from August 2012 to September 2014 and previously as Senior Vice President, Regulatory Affairs and Quality Assurance from August 2008. Mr. Lloyd-Smith served as Vice President and Head of Global Regulatory Affairs for Elan Pharmaceuticals, Inc. from September 2003 to August 2008 after having served in the United Kingdom as its Vice President, International Regulatory Affairs from March 2002 to August 2003. Previously, Mr. Lloyd-Smith served in various positions of increasing responsibility with DuPont Pharmaceuticals in Germany, Switzerland, USA and UK. Mr. Lloyd-Smith holds a B.Sc. in Pharmacology from the University of Leeds and a M.Sc. in Pharmacological Biochemistry from Hatfield Polytechnic.
- Kevin C. Gorman
Kevin C. Gorman，从1993年起，他就职于我公司。2006年前，他担任商业发展执行副总裁、首席商务官和高级副总裁；2006年9月起担任执行副总裁和首席运营官；2008年1月，被任命为总裁和首席执行官。从2008年1月起，他担任我公司董事。从1990至1993年，他是Avalon Medical Partners, L.P。的主席，负责我公司和其他几个生物技术公司如Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc.何ARIAD Pharmaceuticals, Inc.的早期创立。他在洛杉矶University of California获得免疫学博士学位和金融工商管理学硕士学位并在The Rockefeller University完成博士后培训。
Kevin C. Gorman, Ph.D. has been employed with the Company since 1993. He was appointed President and Chief Executive Officer in January 2008 after having served as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. He currently serves as Chief Executive Officer and has served on the Board of Directors since January 2008. From 1990 until 1993 Dr. Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of the Company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr. Gorman received his Ph.D. in immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.- Kevin C. Gorman，从1993年起，他就职于我公司。2006年前，他担任商业发展执行副总裁、首席商务官和高级副总裁；2006年9月起担任执行副总裁和首席运营官；2008年1月，被任命为总裁和首席执行官。从2008年1月起，他担任我公司董事。从1990至1993年，他是Avalon Medical Partners, L.P。的主席，负责我公司和其他几个生物技术公司如Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc.何ARIAD Pharmaceuticals, Inc.的早期创立。他在洛杉矶University of California获得免疫学博士学位和金融工商管理学硕士学位并在The Rockefeller University完成博士后培训。
- Kevin C. Gorman, Ph.D. has been employed with the Company since 1993. He was appointed President and Chief Executive Officer in January 2008 after having served as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. He currently serves as Chief Executive Officer and has served on the Board of Directors since January 2008. From 1990 until 1993 Dr. Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of the Company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr. Gorman received his Ph.D. in immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.
- Christopher F. O'Brien
Christopher F. O'Brien，从2005年起，他担任临床开发高级副总裁并于2007年1月成为首席医疗官，负责临床运营、法规事务、药品安全、生物统计及数据管理。加入Neurocrine之前从2000至2003年，他担任Elan Pharmaceuticals, Inc.的高级副总裁，负责全球区医疗事务，并从2003至2005年，担任Prestwick Pharmaceuticals, Inc.的首席医疗官。他目前是Verifax Corporation的董事会成员，该公司是生物统计公司，专注于开发动态签名认证系统。他是一名得到认证的神经学家，在University of Minnesota获得医学学位并完成住院医生实习期，在Boston University获得神经学学士学位并在University of Rochester School of Medicine获得专科训练。
Christopher F. O'Brien became Chief Medical Officer in January 2007 after having served as Senior Vice President of Clinical Development since 2005. He is responsible for Clinical Operations, Regulatory Affairs, Drug Safety, Biostatistics and Data Management. Prior to joining Neurocrine, he was Chief Medical Officer at Prestwick Pharmaceuticals, Inc. from 2003 to 2005 and Senior Vice President of Global Medical Affairs at Elan Pharmaceuticals, Inc. from 2000 to 2003. Dr. O'Brien is currently on the Board of Directors of Verifax Corporation, a biometrics company focused on developing a dynamic signature verification system. Dr. O'Brien is a Board Certified Neurologist and obtained his undergraduate degree in Neuroscience from Boston University, his medical degree and residency training from the University of Minnesota and fellowship training from the University of Rochester School of Medicine.- Christopher F. O'Brien，从2005年起，他担任临床开发高级副总裁并于2007年1月成为首席医疗官，负责临床运营、法规事务、药品安全、生物统计及数据管理。加入Neurocrine之前从2000至2003年，他担任Elan Pharmaceuticals, Inc.的高级副总裁，负责全球区医疗事务，并从2003至2005年，担任Prestwick Pharmaceuticals, Inc.的首席医疗官。他目前是Verifax Corporation的董事会成员，该公司是生物统计公司，专注于开发动态签名认证系统。他是一名得到认证的神经学家，在University of Minnesota获得医学学位并完成住院医生实习期，在Boston University获得神经学学士学位并在University of Rochester School of Medicine获得专科训练。
- Christopher F. O'Brien became Chief Medical Officer in January 2007 after having served as Senior Vice President of Clinical Development since 2005. He is responsible for Clinical Operations, Regulatory Affairs, Drug Safety, Biostatistics and Data Management. Prior to joining Neurocrine, he was Chief Medical Officer at Prestwick Pharmaceuticals, Inc. from 2003 to 2005 and Senior Vice President of Global Medical Affairs at Elan Pharmaceuticals, Inc. from 2000 to 2003. Dr. O'Brien is currently on the Board of Directors of Verifax Corporation, a biometrics company focused on developing a dynamic signature verification system. Dr. O'Brien is a Board Certified Neurologist and obtained his undergraduate degree in Neuroscience from Boston University, his medical degree and residency training from the University of Minnesota and fellowship training from the University of Rochester School of Medicine.
- Haig P. Bozigian
Haig P. Bozigian，在担任过临床前开发副总裁后，2006年12月，他被任命为首席开发官，负责所有临床前、化学及制药开发。1997年，他加入Neurocrine。由于在CNS相关新产品开发出色的专业知识，他参与了20多年的研发工作。加入Neurocrine前，他担任Procyte Corporation的制药开发董事、Sphinx Pharmaceuticals Corporation的药物动力学与药物代谢助理董事以及GlaxoSmithKline的临床药物动力学师。他在University of Massachusetts获得微生物学学士学位、在University of Nebraska Medical Center获得药效学和毒理学硕士学位并在University of Arizona获得药物科学博士学位。
Haig P. Bozigian, Ph.D. was appointed Chief Development Officer in December 2006 after having served as Vice President of Preclinical Development. He is responsible for all pre-clinical, chemical and pharmaceutical development. Dr. Bozigian joined Neurocrine in 1997. With extensive expertise in CNS related new product development, Dr. Bozigian has participated in research and development for more than 20 years. Prior to joining Neurocrine, Dr. Bozigian served as Director of Pharmaceutical Development at Procyte Corporation, Associate Director of Pharmacokinetics and Drug Metabolism at Sphinx Pharmaceuticals Corporation and as a Clinical Pharmacokineticist at GlaxoSmithKline. Dr. Bozigian earned his B.S. in Microbiology from the University of Massachusetts, his M.S. in Pharmacodynamics and Toxicology from the University of Nebraska Medical Center, and earned his Ph.D. in Pharmaceutical Sciences from the University of Arizona.- Haig P. Bozigian，在担任过临床前开发副总裁后，2006年12月，他被任命为首席开发官，负责所有临床前、化学及制药开发。1997年，他加入Neurocrine。由于在CNS相关新产品开发出色的专业知识，他参与了20多年的研发工作。加入Neurocrine前，他担任Procyte Corporation的制药开发董事、Sphinx Pharmaceuticals Corporation的药物动力学与药物代谢助理董事以及GlaxoSmithKline的临床药物动力学师。他在University of Massachusetts获得微生物学学士学位、在University of Nebraska Medical Center获得药效学和毒理学硕士学位并在University of Arizona获得药物科学博士学位。
- Haig P. Bozigian, Ph.D. was appointed Chief Development Officer in December 2006 after having served as Vice President of Preclinical Development. He is responsible for all pre-clinical, chemical and pharmaceutical development. Dr. Bozigian joined Neurocrine in 1997. With extensive expertise in CNS related new product development, Dr. Bozigian has participated in research and development for more than 20 years. Prior to joining Neurocrine, Dr. Bozigian served as Director of Pharmaceutical Development at Procyte Corporation, Associate Director of Pharmacokinetics and Drug Metabolism at Sphinx Pharmaceuticals Corporation and as a Clinical Pharmacokineticist at GlaxoSmithKline. Dr. Bozigian earned his B.S. in Microbiology from the University of Massachusetts, his M.S. in Pharmacodynamics and Toxicology from the University of Nebraska Medical Center, and earned his Ph.D. in Pharmaceutical Sciences from the University of Arizona.
- Dimitri E. Grigoriadis
Dimitri E. Grigoriadis，2007年1月，他担任首席研究官，监督所有研究功能包括药物发现、生物和化学。1993年，他加入Neurocrine，建立了药理学部门和药物筛选小组，并曾是发现生物学的神经内分泌研究院和副总裁。加入Neurocrine之前从1990至1993年，他担任DuPont Pharmaceutical Company神经系统小组的高级科学家。他在加拿大安大略的University of Guelph获得学士学位。从1987年至1990年，他在National Institute on Drug Abuse完成了博士后研究。
Dimitri E. Grigoriadis, Ph.D. became Chief Research Officer in January 2007 and oversees all research functions, including drug discovery, biology and chemistry. Dr. Grigoriadis joined Neurocrine in 1993 established the pharmacology and drug screening groups and was most recently a Neurocrine Fellow and Vice President of Discovery Biology. Prior to joining Neurocrine, he was a Senior Scientist in the Neuroscience group at the DuPont Pharmaceutical Company from 1990 to 1993. Dr. Grigoriadis received his B.Sc. from the University of Guelph in Ontario, Canada, and his M.Sc. and Ph.D. in Pharmacology from the University of Toronto, Ontario, Canada. He conducted his postdoctoral research at the National Institute on Drug Abuse from 1987 to 1990.- Dimitri E. Grigoriadis，2007年1月，他担任首席研究官，监督所有研究功能包括药物发现、生物和化学。1993年，他加入Neurocrine，建立了药理学部门和药物筛选小组，并曾是发现生物学的神经内分泌研究院和副总裁。加入Neurocrine之前从1990至1993年，他担任DuPont Pharmaceutical Company神经系统小组的高级科学家。他在加拿大安大略的University of Guelph获得学士学位。从1987年至1990年，他在National Institute on Drug Abuse完成了博士后研究。
- Dimitri E. Grigoriadis, Ph.D. became Chief Research Officer in January 2007 and oversees all research functions, including drug discovery, biology and chemistry. Dr. Grigoriadis joined Neurocrine in 1993 established the pharmacology and drug screening groups and was most recently a Neurocrine Fellow and Vice President of Discovery Biology. Prior to joining Neurocrine, he was a Senior Scientist in the Neuroscience group at the DuPont Pharmaceutical Company from 1990 to 1993. Dr. Grigoriadis received his B.Sc. from the University of Guelph in Ontario, Canada, and his M.Sc. and Ph.D. in Pharmacology from the University of Toronto, Ontario, Canada. He conducted his postdoctoral research at the National Institute on Drug Abuse from 1987 to 1990.